<DOC>
	<DOCNO>NCT01124253</DOCNO>
	<brief_summary>This study design determine whether adjuvant vinorelbine plus cisplatin endostar prolongs overall survival compare vinorelbine plus cisplatin alone among patient completely resect IB-IIIA non-small-cell lung cancer .</brief_summary>
	<brief_title>Adjuvant Vinorelbine Plus Cisplatin ( NP ) Versus NP Plus Endostar Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>It open label , randomize , mono-center phase III clinical trail.A total 250 patient resected stage IB stage IIIA non-small cell lung cancer either group vinorelbine plus cisplatin plus endostar group vinorelbine plus cisplatin randomly . The primary end point overall survival ; principal secondary end point recurrence-free survival toxicity safety regimens.The major inclusive criterion pathological confirm non-small cell lung cancer complete resection tolerate chemotherapy safely.The tissue blood sample bank investigation . All enrol patient follow death 5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer , pathology type include squamous cell carcinoma , adenocarcinoma , largecell carcinoma , mixed type 3 type mention . Stage IBIIIA nonsmall cell lung cancer , tumor completely resect ( The type surgery include lobectomy , leave side pneumonectomy , bilobectomy ) . The time surgery first dose adjuvant chemotherapy mandatory 48 week . No evidence tumor relapse prior adjuvant therapy . Age 1870 , Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Normal hematologic function.Renal function , hepatic cardiac function within acceptable range follow : serum bilirubin , aspartate aminotransferase ( AST ) alamine aminotransferase ( ALT ) level 1.5 time normal value . No history chemotherapy radiotherapy ; The patient well compliance chemotherapy follow Informed consent obtain treatment . The histological cytological document match inclusion criterion . Right side pneumonectomy kind incompletely resect surgery . The recruitment time beyond 8 week surgery . Any concurrent acute chronic systemic disease psychiatric disease , might increase risk research medical therapy influence research result analysis . The researcher make judge follow condition tell whether fit research : Uncontrolled high blood pressure , unstable angina , myocardial infarction , uncontrolled arrhythmia , congestive heart failure clinical symptom within 12 week randomization.Evidence anemia electrocardiographic manifestation heart valve disease confirm clinical diagnosis.Clinically significant active infection state due bacteria , virus fungi invasion . Patients grade II arrhythmia , grade II myocardial anemia , grade II abnormal cardiac troponin T , grade II high blood pressure leave ventricle ejection fraction ( LVEF ) less 50 percent accord CTC 3.0 permit enrol study . woman pregnant lactation . Before enter group , patient malignant tumor except nonmelanoma skin cancer , carcinoma situ cure earlystage prostate cancer . With allergic constitution possible allergic reflection know research drug . Poor compliance . Not proper research accord researcher ' judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>adjuvant therapy</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>recombinant human endostatin</keyword>
	<keyword>endostar</keyword>
</DOC>